Current and future clinical trials for alzheimer s disease: Evolving ethical concerns

Baskin, 1998, Barriers to obtaining consent in dementia research: implications for surrogate decision-making, J. Am. Geriatr. Soc., 46, 287, 10.1111/j.1532-5415.1998.tb01039.x Berg, 1996, Legal and ethical complexities of consent with cognitively impaired research subjects: proposed guidelines, J. Law Med. Ethics, 24, 18, 10.1111/j.1748-720X.1996.tb01830.x Birge, 1997, The role of estrogen in the treatment of Alzheimer's disease, Neurology, 48, S36, 10.1212/WNL.48.5_Suppl_7.36S Bodick, 1997, Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease, Arch Neurol., 54, 465, 10.1001/archneur.1997.00550160091022 Bondi, 1995, Episodic memory changes are associated with the APOE — EPSILON 4 allele in nondemented older adults, Neurol., 45, 2203, 10.1212/WNL.45.12.2203 Breitner, 1994, Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study, Neurol., 44, 227, 10.1212/WNL.44.2.227 Breitner, 1995, Delayed onset of the Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs, Neurobiol. Aging, 16, 523, 10.1016/0197-4580(95)00049-K Brodaty, 1995, Consensus statement on predictive testing for Alzheimer disease, Alz. Dis. Assoc. Disord., 9, 182, 10.1097/00002093-199509040-00002 1994, Canadian Study of Health and Aging: Study methods and prevalence of dementia, Can. Med. Assoc. J., 150, 899 Alzheimer, 1995, Statement on Use of Apolipoprotein E Testing for Alzheimer Disease, JAMA, 274, 1627, 10.1001/jama.1995.03530200063039 1996, Lancet, 347, 1091, 10.1016/S0140-6736(96)90284-6 Corder, 1993, Gene dose of apolipoprotein E type 4 Allele and the risk of Alzheimer's disease in late onset families, Science, 261, 921, 10.1126/science.8346443 Council for International Organizations of Medical Sciences (CIOMS) — World Health Organization, 1993 Cummings, 1998, Metrifonate treatment of the cognitive deficits of Alzheimer's disease, Neurol., 50, 1214, 10.1212/WNL.50.5.1214 Davis, 1992, A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease, N. Engl. J. Med., 327, 1253, 10.1056/NEJM199210293271801 Davis, 1998, Future therapeutic approaches to Alzheimer's disease, J. Clin. Psychiatry, 59, 14 1995, Declaration of Helsinki, 5, 2765 Doody, 1999, Impact of new therapies on Alzheimer's disease management. Introduction, Gerontology, 45, 1 Doody, 1999, Clinical profile of donepezil in the treatment of Alzheimer's disease, Gerontology, 45, 23, 10.1159/000052761 Drachman, 1997, Treatment of Alzheimer's disease — searching for a breakthrough, settling for less, N. Engl. J. Med., 336, 1245, 10.1056/NEJM199704243361710 Eikelenboom, 1994, Inflammatory mechanisms in Alzheimer's disease, Trends Pharmacol. Sci., 15, 447, 10.1016/0165-6147(94)90057-4 Farlow, 1996, Apolipoprotein E genotype and gender influence response to tacrine therapy, Ann. NY Acad. Sci., 802, 101, 10.1111/j.1749-6632.1996.tb32603.x Farlow, 1998, New treatments in Alzheimer disease and the continued need for placebo-controlled trials, Arch. Neurol., 55, 1396, 10.1001/archneur.55.11.1396 Farlow, 1998, Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease, Neurol., 50, 669, 10.1212/WNL.50.3.669 Ferris, 1997, Objective psychometric tests in clinical trials of dementia drugs, Alz. Dis. Assoc. Disord., 11, 34 Filip, 1999, Selegiline in the treatment of Alzheimer's disease: A long-term randomized placebo-controlled trial, J. Psychiatry Neurosci., 24, 234 Forette, 1998, Drug development in Alzheimer's disease: a review of its history and a preview of its future, 1 Freedman, 1987, Equipoise and the ethics of clinical research, N. Engl. J. Med., 317, 141, 10.1056/NEJM198707163170304 Gauthier, 1997, Alzheimer's disease: current knowledge, management and research, CMAJ, 157, 1047 Qauthier, 1999, Managing expectations in the long-term treatment of Alzheimer's disease, Gerontology, 45, 33 Ghika, 1995, Toward a treatment for dementia, Schweizerische Rundschau fur Medizin Praxis, 84, 1050 Glass, 1991, Informed consent to medical research on persons with Alzheimer's disease: ethical and legal parameters, 30 Goate, 1991, Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease, Nature, 349, 704, 10.1038/349704a0 Henderson, 1995, Apolipoprotein E allele e4, dementia, and cognitive decline in a population sample, Lancet, 346, 1387, 10.1016/S0140-6736(95)92405-1 High, 1992, Research with Alzheimer's disease subjects: informed consent and proxy decision making, J. Am. Geriatr. Soc., 40, 950, 10.1111/j.1532-5415.1992.tb01995.x Hux, 1998, Relation between severity of Alzheimer's disease and costs of caring, CMAJ, 159, 457 Itil, 1998, The pharmacological effects of Ginkgo bilboa, a plant extract, on the brain of dementia patients in comparison with tacrine, Psychopharmacol. Bull., 34, 391 Kalaria, 1996, Cellular aspects of the inflammatory response in Alzheimer's disease, Neurodegen., 5, 497, 10.1006/neur.1996.0069 Kanowski, 1996, Proof of efficacy of the ginkgo biloba special extract Egb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia, Pharmacopsych., 29, 47, 10.1055/s-2007-979544 Karlawish, 1998, Is the placebo control obsolete in a world after donepezil and vitamin E?, Arch. Neurol., 55, 1420, 10.1001/archneur.55.11.1420 Kawas, 1999, Clinical trials in Alzheimer's disease: Debate on the use of placebo controls, Alz. Dis. Assoc. Disord., 13, 124, 10.1097/00002093-199907000-00002 Keyserlingk, 1995, Proposed guidelines for the participation of persons with dementia as research subjects, Persp. Biol. Med., 38, 319, 10.1353/pbm.1995.0049 Kittner, 1997, Clinical trials in dementia with propentofylline, Ann. NY Acad. Sci., 826, 307, 10.1111/j.1749-6632.1997.tb48481.x Knopman, 1998, Clinical research designs for emerging treatments for Alzheimer disease: Moving beyond placebo-controlled trials, Arch. Neurol., 55, 1425, 10.1001/archneur.55.11.1425 Lebars, 1997, A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia, JAMA, 278, 1327, 10.1001/jama.1997.03550160047037 Leber, 1990 Levy-Lahad, 1995, Candidate gene for the chromosome 1 familial Alzheimer's disease locus, Science, 269, 973, 10.1126/science.7638622 Lipsky, 1999, Role of cyclooxygenase-1 and -2 in health and disease, Am. J. Ortho., 28, 8 Maestre, 1995, Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks, Ann. Neurol., 37, 254, 10.1002/ana.410370217 Marcusson, 1997, A 12-month, randomized, placebo-controlled trial of propenntofylline (HWA 285) in patients with dementia according to DSM III-R, Dement. Geriatr. Cogn. Disord., 8, 320, 10.1159/000106650 Mayeux, 1993, The apolipoprotein ε allele in patients with Alzheimer's disease, Ann. Neurol., 34, 752, 10.1002/ana.410340527 McGeer, 1996, Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies, Neurol., 47, 425, 10.1212/WNL.47.2.425 McGeer, 1999, Inflammation of the brain in Alzheimer's disease: implications for therapy, J. Leukocyte Biol., 65, 409, 10.1002/jlb.65.4.409 Miller, 1992, Ethical standards for human subject research in developing countries. IRB: A Review of Human Subjects Research, 14, 7, 10.2307/3563720 Mohr, 1995, Canadian guidelines for the development of antidementia therapies: A conceptual summary, Can. J. Neurol. Sci., 22, 62, 10.1017/S0317167100040543 Morris, 1993, The Clinical Dementia Rating (CDR): current version and scoring rules, Neurol., 43, 2412, 10.1212/WNL.43.11.2412-a National Bioethics Advisory Commission, 1998, Research involving persons with mental disorders that may affect decisionmaking capacity: Report and recommendations of the National Bioethics Advisory Commission, Vol I National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1978 National Institute of Health, Office of Extramural Research, Office FOR Protection from Research Risks, 1993, Protecting Human Subjects: International Review Guidebook Oken, 1998, The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease, Arch. Neurol., 55, 1409, 10.1001/archneur.55.11.1409 Østbye, 1994, Net economic costs of dementia in Canada, Can. Med. Assoc. J., 151, 1457 Patterson, 1999, The recognition, assessment and management of dementing disorders: Conclusions from the Canadian Conference on Dementia, Can. Med. Assoc. J., 160, S1 Pericak-Vance, 1997, Complete genomic screen in late-onset familial Alzheimer disease: Evidence for a new locus on chromosome 12, JAMA, 278, 1237, 10.1001/jama.1997.03550150041033 Poirier, 1993, Apolipoprotein E polymorphism and Alzheimer's disease, Lancet, 342, 697, 10.1016/0140-6736(93)91705-Q Poirier, 1995, Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease, 92, 12260 Poirier, 1997, Neurobiology of apolipoprotein E in the normal brain and in Alzheimer's disease, 93 Polvikoski, 1995, Apolipoprotein E, dementia, and cortical deposition of β-amyloid protein, N. Engl. J. Med., 333, 1242, 10.1056/NEJM199511093331902 Post, 1997, Slowing the progression of Alzheimer disease: Ethical issues, Alz. Dis. Assoc. Disord., 11, S34 Post, 1997, Consensus Statement: The clinical introduction of genetic testing for Alzheimer disease, JAMA, 277, 832, 10.1001/jama.1997.03540340066035 Qizilbash, 1998, Cholinesterase inhibition for Alzheimer disease: A meta-analysis of the tacrine trials, JAMA, 280, 1777, 10.1001/jama.280.20.1777 Rabins, 1998, Developing treatment guidelines for Alzheimer's disease and other dementias, J. Clin. Psychiatry, 59, 17 Richard, 1997, APOE genotyping and response to drug treatment in Alzheimer's disease, Lancet, 349, 539, 10.1016/S0140-6736(97)80089-X Rogaeva, 1998, Evidence for an Alzheimer disease susceptibility locus on chromosome 12 and for further locus heterogeneity, JAMA, 280, 614, 10.1001/jama.280.7.614 Rogaeva, 1995, Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome I related to the Alzheimer type 3 gene, Nature, 376, 775, 10.1038/376775a0 Rogers, 1998, Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study, Arch. Intern. Med., 158, 1021, 10.1001/archinte.158.9.1021 Rogers, 1998, A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease, Neurology, 50, 136, 10.1212/WNL.50.1.136 Roses, 1995, Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease, Ann. Neurol., 38, 6, 10.1002/ana.410380105 Roses, 1996, The Alzheimer diseases, Curr. Opin. Neurobiol., 6, 644, 10.1016/S0959-4388(96)80098-5 Rother, 1998, Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials, Dement. Geriatr. Cogn. Disord., 9, 36, 10.1159/000051188 Sano, 1997, A controlled trial of selegiline, alpha-tocopherol, or both as treatment of Alzheimer's disease, N. Engl. J. Med., 336, 1216, 10.1056/NEJM199704243361704 Saunders, 1993, Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer's disease, Neurol., 43, 1467, 10.1212/WNL.43.8.1467 Schneider, 1996, Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease, Neurol., 46, 1580, 10.1212/WNL.46.6.1580 Schneider, 1997, Validity and reliability of the Alzheimer's Disease Cooperative Study — Clinical Global Impression of Change, Alz. Dis. Assoc. Disord., 11, S22, 10.1097/00002093-199700112-00004 Schneider, 1999, Interpreting and applying clinical trial results in Alzheimer's disease, Alzheimer Insights, 5, 1 Seiger, 1993, Intracranial infusion of purified nerve growth factor to an Alzheimer patient: a first attempt of a possible future treatment strategy, Behav. Brain Res., 57, 255, 10.1016/0166-4328(93)90141-C Seshardi, 1995, Apolipoprotein E4 allele and the lifetime risk of Alzheimer's disease, Arch. Neurol., 52, 1074, 10.1001/archneur.1995.00540350068018 Sherrington, 1995, Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease, Nature, 375, 754, 10.1038/375754a0 Small, 1998, The pathogenesis of Alzheimer's disease, J. Clin. Psychiatry, 59, 7 Soininen, 1996, Apolipoprotein E, memory and Alzheimer's disease, Trends Neurosci., 19, 224, 10.1016/0166-2236(96)10027-8 St. George-Hyslop, 1987, The genetic defect causing familial Alzheimer's disease maps on chromosome 21, Science, 235, 885, 10.1126/science.2880399 Swartz, 1999, Apolipoprotein E and Alzheimer's disease: a genetic, molecular and neuroimaging review, Can. J. Neurol. Sci., 26, 77 Tang, 1996, Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease, Lancet, 348, 1027, 10.1016/S0140-6736(96)03356-9 1998 Willmer, 1998, Evaluation of selection criteria used in Alzheimer's disease clinical trials, Can. J. Neurol. Sci., 25, 39, 10.1017/S0317167100033461 Van Duijn, 1994, Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease, Nat. Genet., 7, 74, 10.1038/ng0594-74 Van Reekum, 1999, Diagnosis of dementia and treatment of Alzheimer's disease. Pharmacologic management of disease progression and cognitive impairment, Can. Family Phys., 45, 945 Yaffe, 1997, Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women, Arch. Neurol., 54, 1110, 10.1001/archneur.1997.00550210044011